TABLE 2.
Physician‐reported responses in evaluable patients
| Response parameter a | Response‐evaluable patients (N = 150) |
|---|---|
| ORR, % | 48.0 |
| DCR, % b | 72.7 |
| Confirmed BOR, n (%) | |
| CR | 38 (25.3) |
| PR | 34 (22.7) |
| SD | 37 (24.7) |
| PD c | 41 (27.3) |
| Duration of treatment in patients with response d | |
| Median (range), mo | 7.4 (1.0‐41.7) |
Abbreviations: BOR, best overall response; CR, complete response; DCR, disease control rate; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.
Response was reported according to the treating physician's assessment of follow‐up scans at the time of resupply.
Among patients treated for a minimum of 3 months with available data.
Patients with PD or adverse events that required treatment discontinuation within the first 90 days were never resupplied with drug and did not have a follow‐up response evaluation; thus, these values may be underreported.
Duration of avelumab treatment/drug supply is reported as a surrogate for duration of response or clinical benefit.